Jianfeng Group Lin2016 -028 (Announcement on Acceptance Notice of Drug Clinical Trial Application of Subsidiary Company)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2016-028
Bond Abbreviation: 13 Peak 01 Bond Code: 122227
Bond Abbreviation: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Acceptance Notice of Subsidiary Drug Clinical Trial Application
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
1. Summary
Recently, Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), a controlling subsidiary of the Company, received the Notice of Acceptance of Drug Registration Application (Acceptance No.: CXHL1600201 Zhejiang) and (Acceptance No.: CXHL1600202 Zhejiang) issued by Zhejiang Food and Drug Administration. The clinical research application of deoxypodophyllotoxin for injection (acceptance number: CXHL1600202 Zhejiang) and its bulk drug (acceptance number: CXHL1600201 Zhejiang) (hereinafter collectively referred to as "DPT") developed by Jianfeng Pharmaceutical and China Pharmaceutical University has been accepted by Zhejiang Food and Drug Administration.
2. drug basic information content
(I) deoxypodophyllotoxin
drug name: deoxypodophyllotoxin
dosage form: non-preparation: bulk drug
packing specification: 2Kg
per bag application item: chemical drug: class 1
Application Stage: Clinical
Applicant: Zhejiang Jianfeng Pharmaceutical Co., Ltd., China Pharmaceutical University
Application Acceptance Number: CXHL1600201 Zhejiang
Conclusion: After formal examination, the application materials basically meet the requirements of the "Measures for the Administration of Drug Registration" and other relevant regulations and are accepted. Approval is subject to review.
(II) Deoxypodophyllotoxin for Injection
Drug Name: Deoxypodophyllotoxin for Injection
Dosage Form: Preparation: Chinese Pharmacopoeia Dosage Form Injection
Specification: 100mg Package Specification: 1 bottle per box
Application Item: Chemical Drug: 1 Class
Application Stage: clinical
Applicant: Zhejiang Jianfeng Pharmaceutical Co., Ltd. and China Pharmaceutical University
Application Acceptance Number: CXHL1600202 Zhejiang
Conclusion: After formal examination, the application materials basically meet the requirements of the "Measures for the Administration of Drug Registration" and other relevant regulations and are accepted. Approval is subject to review.
3. Drug Research and Development and Registration
DPT Project is a new anti-tumor drug developed by Jianfeng Pharmaceutical in cooperation with China Pharmaceutical University in March 112. Domestic and foreign listed alkaloids of similar drugs include: paclitaxel, vinorelbine. DPT indication/ function indication is tentatively designated as first-line and second-line treatment of lung cancer, breast cancer and gastric cancer; Especially for the treatment of the above tumors resistant to paclitaxel and vinorelbine.
DPT is currently in the stage of applying for clinical trial approval. After the clinical application of is accepted, the clinical research work can only be carried out after passing the review and approval of the State Food and Drug Administration (CFDA) and obtaining the clinical trial approval document. After the clinical trial is completed, the production can be applied, after passing the review and approval of CFDA and obtaining the drug production approval, can be produced and marketed.
Up to now, the accumulated research and development investment and other related expenditures of DPT project of Jianfeng Pharmaceutical Co., Ltd. are about 33 million yuan. The impact of
4. on listed companies and risk tips
DPT clinical application filed by the company has been accepted and will not have a significant impact on the company's recent operating results. After the clinical application of
is accepted, the clinical research work can only be carried out after passing the review and approval of CFDA and obtaining the clinical trial approval document. The results and time of the inspection, review and approval during the period are uncertain. Due to the long cycle and high risk of new drug research and development, the company will timely fulfill the obligation of information disclosure according to the progress of research and development. Please pay attention to the investment risk.
hereby announce
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
August 25, 2016
More information
Chairman Jiang Xiaomeng was named "Fengyun Zhejiang Merchants"
On the evening of January 13, the 2021 "Fengyun Zhejiang Merchants" award ceremony was held in Hangzhou. Ten outstanding Zhejiang businessmen, including Jiang Xiaomeng, chairman of the group company, won the honor. The annual "Fengyun Zhejiang Merchants" selection activity is guided by the Propaganda Department of the Zhejiang Provincial Committee of the Communist Party of China, sponsored by Zhejiang Radio and Television Group, and co-organized by Zhejiang Economic Television, Qianjiang Evening News and Zhejiang Merchants Magazine. Provincial Department of Economics and Information Technology, Provincial Department of Science and Technology, Provincial Department of Commerce, Provincial Federation of Industry and Commerce and many other units jointly co-organized. Since its establishment in 2003, it has been held for 18 sessions, and more than 180 "Fengyun Zhejiang businessmen" have been selected. They are all successful models and fresh samples of Zhejiang's economic development.
2022
01-17
Peak re-listed China's top 100 building materials enterprises
China Building Materials Enterprise Management Association recently released a series of lists of "2021 Top 500 Chinese Building Materials Enterprises", and Jianfeng Group ranked among the "2021 Top 100 Chinese Building Materials Enterprises". This series of lists has been released every year since 2002, and has received extensive attention and active participation from governments at all levels, building materials authorities and building materials companies. It has become a vane of China's building materials industry. Since participating in the selection of the list, the peak has been ranked among the top 100 building materials enterprises in China for many years.
2022
01-04
Hubei "Wisdom and Energy Saving" Focus on Daye Peak
On the morning of December 3, more than 180 people from relevant competent departments at all levels and key energy consuming units in Hubei Province gathered in Daye Jianfeng cement company to visit and understand Daye Jianfeng's practice and experience in intelligent energy conservation. On the same day, the provincial smart energy-saving training meeting organized by the Hubei Provincial Development and Reform Commission was held in daye city. daye peak was the only visiting enterprise arranged for the meeting.
2021
12-13
Daye Peak passed the intellectual property management system certification.
Recently, Daye Jianfeng Cement Company received the intellectual property management system certification certificate issued by Guozhi (Beijing) Certification Company. This is also the first system certificate obtained by the company to implement the intellectual property management standard certification. In recent years, Daye Jianfeng has actively mobilized employees to carry out technological innovation, invention and creation, and timely summarized technological achievements and filed patents. Up to now, it has obtained 31 invention patents and utility model patents. At the same time, Daye's concept of the creation, application, management and protection of intellectual property rights is also increasing, and it continues to increase the promotion of new products and new technologies with high value-added intellectual property rights, and enhance the value of corporate intangible assets. Intensity. The passing of this system certification can not only obtain government incentives and funding, but also the basic conditions for intellectual property work and the prerequisite for applying for related projects.
2021
12-13
In order to quickly set off an upsurge of studying and implementing the spirit of the Sixth Plenary Session of the 19th Central Committee of the Party, and effectively unify thoughts and actions into the decision-making and deployment of the Party Central Committee with Comrade Xi Jinping as the core, and earnestly learn in the depths, seek new places, and do In practice, on December 1, the party committee of the group company held a spiritual lecture at the Sixth Plenary Session of the 19th Central Committee, which was delivered by Jiang Xiaomeng.
2021
12-13
Group Party Committee to Learn the Spirit of the Sixth Plenary Session of the 19th Central Committee
On the afternoon of November 18, the Party Committee of the Group held a special meeting to learn the spirit of the Sixth Plenary Session of the 19th CPC Central Committee and make arrangements for in-depth study. The Sixth Plenary Session of the 19th Central Committee of the Communist Party of China is an important meeting of overall and historical significance held at the historical intersection of the "two centenary" goals on the occasion of celebrating the centenary of the Communist Party of China. The "Resolution of the Central Committee of the Communist Party of China on the Major Achievements and Historical Experience of the Party's Hundred Years of Struggle" approved by the plenary session is a Marxist programmatic document that inherits the past and the future. It is also an action guide to learn from history, create the future, and realize the great rejuvenation of the Chinese nation. At the special meeting, Jiang Xiaomeng, Secretary of the Party committee of the group, and all the members of the Party committee, from the great achievements, historical significance and historical experience created by the party's 100 year history, since the 18th National Congress of the Communist Party of China, it has adhered to the party's overall leadership, comprehensive and strict governance of the party, economic construction, comprehensive deepening of reform and opening up, political construction, comprehensive rule of law, cultural construction, social construction, ecological civilization construction, national defense and military construction, and maintenance of national security., Adhere to the "one country, two systems" and promote the reunification of the motherland, diplomatic work and other 13 important achievements, comprehensively interpret and study the resolutions of the plenary session.
2021
11-22